KMTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kestra Medical Technologies Ltd (KMTS) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has shown impressive revenue growth and improving gross margins, the recent price decline, lack of strong technical indicators, and neutral sentiment from hedge funds and insiders suggest a cautious approach. Additionally, the absence of recent positive news or significant trading signals further supports a hold recommendation.
The MACD is negatively expanding (-0.184), indicating bearish momentum. RSI is at 27.072, which is neutral but approaching oversold territory. Moving averages are converging, showing no clear trend. The stock is trading near its S1 support level (24.484), with resistance at 27.724. Overall, the technical indicators do not suggest a strong buying opportunity.
Strong Q2 financial performance with 53.4% YoY revenue growth and gross margin improvement to 50.63%.
Analysts have highlighted the company's market share gains and improving profitability profile.
Raised FY26 sales guidance to $91M, showing confidence in future growth.
Recent price decline of -2.77% and weak market sentiment in the MedTech sector.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
Analysts have a mixed view, with Goldman Sachs maintaining a Neutral rating and lowering the price target to $
No recent news or event-driven catalysts to drive immediate positive sentiment.
In Q2 2026, Kestra Medical reported revenue of $22.57M, up 53.4% YoY. Net income improved to -$32.79M, up 38.39% YoY. EPS increased to -0.64, up 33.33% YoY. Gross margin rose to 50.63%, reflecting a 27.76% improvement YoY. Despite strong revenue growth and margin expansion, the company remains unprofitable.
Analysts have mixed views. Goldman Sachs recently lowered the price target to $24 from $27, citing sector-wide weakness. However, other analysts like Piper Sandler and Stifel have raised price targets, highlighting strong financial performance and market share gains. The consensus rating appears neutral to slightly positive, with no strong buy signals.
